Irritable Bowel Syndrome Drugs Segmentation
Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}
The IBS with diarrhea (IBS-D) segment is predicted to dominate market share over the projected time frame. The segment growth can be attributed to increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.
Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Irritable Bowel Syndrome Drugs Market in 2025 is estimated at USD 4.43 billion.
The global market size was around USD 4.14 billion in 2024 and is likely to expand at a CAGR of more than 8.7%, surpassing USD 12.25 billion revenue by 2037.
North America takes the lead, driven by fecal incontinence treatment needs and efficient care options.
The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.
